Prophylactic neutralization of IL-21 with monoclonal antibodies significantly improved GVHD outcomes by reducing weight loss and mortality, while modulating T cell responses through increased Tregs and decreased IFN-γ/granzyme B-producing T cells. The gene discussed is IL21; the disease is graft versus host disease.